A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy — a cell-based cancer treatment that exploded on the scene in 2017 as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results